BMO Capital raised the firm’s price target on Alnylam (ALNY) to $470 from $450 and keeps an Outperform rating on the shares. The firm contends that the 9.2mmHg SBP lowering in KARDIA-3 subgroup positions Zilebesiran well for a successful CVOT, cardiovascular outcomes trial, while Zilebesiran’s MoA, Q6M regimen, Part B reimbursement, and commercialization by Alnylam / Roche (RHHBY) set Zilebesiran up for a promising commercial trajectory, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy Treatment
- Alnylam’s Vutrisiran Study Advances in Treating Rare Cardiomyopathy
- Cautious Hold Rating for Alnylam Pharma Amid Uncertain Efficacy of Zilebesiran in KARDIA-3 Trial
- Alnylam price target raised to $583 from $527 at Citi
- Positive Outlook on Alnylam Pharma’s Hypertension and ATTR-CM Developments